Virus Filtration Market - Global Industry Analysis

Table Of Content

Methodology

Free Analysis

Nowadays, biological drugs such as biosimilars and recombinant vaccines require advanced GMP’s to fall it into all the aspects of drug approval. As the pharmaceutical industry is advancing, many potential biological therapeutic drugs are being introduced to the market. These biological drugs are prone to viral contamination which could lead to huge economic loss to a manufacturer. The virus filters provide an advanced solution to the viral contamination. It is being widely adopted in the production of biological drugs, in stem cell products, medical device, air, and water purification, tissue and tissue products, cellular and gene therapy products. The prospering biopharmaceutical industry increased capital expenditure on research and increasing government support for pharmaceutical and biotechnology industries are the major driving factors for the virus filtration market. However, the high cost of virus filtration systems and strict government regulations are the major factors restraining the growth of virus filtration market. On the other hand, untapped markets in developing countries and rapid technological advancements in virus filtration solutions are expected to offer lucrative opportunities during the forecast period.

By product, the global virus filtration market is divided into filtration systems, kits & reagents, services, and others. Among these filtration systems segment was the highest revenue grosser in 2017. Virus filtration is a common unit operation in the manufacture of biological drugs. The increasing the demand for these diagnostic care and CRO’s are expected to poise the growth of kits and reagent in coming years.

On the basis of application, the market is segmented into biologicals, vaccines and therapeutics, blood and blood products, stem cell products, medical device, air purification and water purification, tissue and tissue products, and cellular and gene therapy products.

The end users in the virus filtration market are pharmaceutical & biotechnology companies, contract research organizations, academic research institutes, and medical device companies. The pharmaceutical and biotechnological companies dominated the market and accounted for the largest share in 2017. The bulky share of this segment is primarily credited to the prime factors such as growing need of virus retention in the product feed and the growing stringent regulatory policies for drug approvals. The contract research organization segment is expected to grow at the highest CAGR during the forecast period.

Based on the geography, the global virus filtration market is divided into five regions, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to remain the dominant region over the forecast period. Europe was the second largest market followed by the Asia Pacific. Asia Pacific anticipates being the fastest growing market with the highest CAGR during the forecast period. Developing economies such as India and China are accelerating the growth of this region owing to the development of healthcare infrastructure and heightened corporate investments in the healthcare sector. The Middle East and Africa and Latin America are expected to experience moderate growth in the virus filtration market in the years to come. 

Some of the key players in virus filtration market include Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group Ltd., Pall Corporation, Charles River Laboratories International, Inc., Sartorius AG, Sigma-Aldrich Corporation, Asahi Kasei Medical Co., Ltd., WuXi PharmaTech Inc., and General Electric Company, among others.